Integrating the Latest Data and Guidelines in the Management of Insomnia: Utilizing New Therapies for Optimal Clinical and Economic Outcomes

A continuing medical education activity provided by NAMCP and AAMCN

Novel Treatment Advances and Approaches in the Management of Insomnia: Managed Care Considerations in an Evolving Management Paradigm is a three-part webinar series

This is Part 1 of the series focusing on optimal clinical and
economic outcomes in the management of insomnia

This activity is an archive from the webinar held October 23, 2020

This activity is valid from December 1, 2020 to December 1, 2022

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.
 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from Eisai

Description:
Insomnia is a sleep disorder which makes it difficult to fall asleep or stay asleep, even when a person has the chance to do so. This can affect a person’s sleep so much that they still feel tired after they wake up. The dangers of insomnia can affect more than just a person’s mood as people and if not treated properly can lead to other effects such as anxiety, depression, irritability, concentration problems, memory problems, poor immune system function, and reduced reaction time. There are 60 million Americans affected by the disease. About 25% of Americans experience acute insomnia each year with around 10% experiencing chronic insomnia.

 Upon completion of this activity, participants will be able to:

  • Describe the clinical and economic impact of insomnia on quality of life and risk of psychiatric and physical illnesses

  • Examine treatment guidelines and differentiate current and newer treatments, including efficacy and safety considerations

  • Apply the latest clinical data on novel and emerging therapies, including dual orexin receptor antagonists, to the treatment of patients with insomnia

  • Examine the clinical data for the safety and efficacy profiles for pharmacologic therapies for the treatment of insomnia and untreated insomnia

     

Faculty: Karl Doghramji, MD
Professor of Psychiatry, Neurology, and Medicine
Director, Jefferson Sleep Disorders Center
Program Director, Fellowship in Sleep Medicine
Thomas Jefferson University

Disclosure:

 Dr. Doghramji serves as a consultant for Eisai, Harmony, Jazz, Teva, Merck, and Pfizer. He has received research/grant support from Jazz, Eisai, Harmony, and Inspire. He owns stock in Merck. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from Eisai
 

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue